Printer Friendly

AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS

           AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
    SAN DIEGO, Nov. 1 /PRNewswire/ -- Agouron Pharmaceuticals Inc.


(NASDAQ-NMS: AGPH) today announced a net loss of $2,107,000 or $.43 per common share, on revenues of $1,096,000 for the quarter ended Sept. 30, 1991. The net loss recorded in the comparable period of the prior fiscal year was $1,588,000, or $.37 per common share, on revenues of $1,100,000. Operating results for the first three months of the fiscal year reflect Agouron's continuing investment in proprietary research and development activities.
    Agouron Pharmaceuticals Inc. is a pioneer and leader in a new technology for the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease.  Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS, and other serious diseases.
                     AGOURON PHARMACEUTICALS INC.
                    Summary Financial Information
                                            Three Months Ended
                                                 Sept. 30,
                                             1991        1990
    Revenues                             $1,096,000   $1,100,000
    Net loss                            ($2,107,000) ($1,588,000)
    Net loss per common share              ($.43)       ($.37)
    Shares used in computing
     net loss per common share            4,883,000    4,242,000
    -0-                    11/1/91
    /CONTACT:  Steven S. Cowell, vice president & CFO or Donna Nichols, 619-622-3000, of Agouron Pharmaceuticals Inc.
    (AGPH) CO:  Agouron Pharmaceuticals Inc. ST:  California IN:  MTC SU:  ERN EH-KJ -- SD001 -- 0455 11/01/91 18:10 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1991
Words:237
Previous Article:MAGMA COPPER CLOSES PURCHASE OF REMAINING INTEREST IN ROBINSON
Next Article:NUVEEN EXCHANGE-TRADED FUNDS DECLARE TAX-FREE DIVIDENDS
Topics:


Related Articles
AGOURON PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1992 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1993 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1995 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
Agouron Pharmaceuticals Reports First Quarter 1997 Financial Results
Agouron Pharmaceuticals Reports Fourth Quarter and Fiscal 1997 Financial Results; Announces 2 For 1 Stock Split

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters